4547:TYO
Kissei Pharmaceutical Co Ltd
3 725,00 JP¥
arrow_upward
+0,81%(+30,00) 1D
9 հոկ, 10:43:51 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
3 725 JP¥
High
3 745 JP¥
Low
3 705 JP¥
Mkt. cap
172,04 մլրդ
Avg. vol.
69,32 հզր
Volume
18,30 հզր
Dividend
3,22%
Quarterly dividend
30 JP¥
Ex-dividend date
29 սեպ, 2026 թ.
P/E ratio
11,04
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 մլն
No. of employees
2 հզր
Open
3 725 JP¥
High
3 745 JP¥
Low
3 705 JP¥
Mkt. cap
172,04 մլրդ
Avg. vol.
69,32 հզր
Volume
18,30 հզր
Dividend
3,22%
Quarterly dividend
30 JP¥
Ex-dividend date
29 սեպ, 2026 թ.
P/E ratio
11,04
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
CNBC
·
2 ժամ առաջ
Tokenization could unleash tens of billions of dollars in trapped capital, Nasdaq CEO says
The National Law Review
·
2 րոպե առաջ
Kaplan Fox Encourages Honeywell Aerospace Inc. (NASDAQ: HONA) Inv
Yahoo Finance
·
16 րոպե առաջ
Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?
Investor's Business Daily
·
1 ժամ առաջ
Dow Jones Futures: AI Stocks Tumble On OpenAI News; SpaceX Move Slams Verizon, AT&T Late
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 հզր
Founded09 օգս, 1946 թ.
HeadquartersՄացումոտո, Nagano, Ճապոնիա
Sector-
Websitekissei.co.jp